Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, said Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University.
Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University, said at the 56th ASH Annual Meeting in San Francisco, December 6-9, 2014.
“Then the question was: ‘What can we do with those differences?’” she said.
Now that they know how stem cells behave, they can understand how cancer stem cells communicate differently with their environment and identify which of the hundred of changes are fueling the cancer.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen